---
schema_version: "secwatch.filing_event.v1"
accession: "0001739104-24-000036"
form_type: "8-K"
ticker: "ELAN"
cik: "0001739104"
company_name: "Elanco Animal Health Inc"
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:40:31.706341+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Elanco Q3 revenue $1.03B, +1% organic; adj. EPS $0.13; 2024 guidance tightened

## Summary
- Reported net income $364M ($0.73 EPS) includes $640M pre-tax gain from July aqua divestiture; adjusted net income $66M ($0.13 EPS).
- Full-year 2024 guidance tightened: revenue $4.42-$4.45B, adj. EBITDA $900-$930M, adj. EPS $0.89-$0.95 (midpoint unchanged).
- U.S. FDA approved Zenrelia (JAK inhibitor for atopic dermatitis in dogs) and Credelio Quattro (broad-spectrum parasiticide).
- Net leverage ratio 4.3x, down from 5.6x at June 30; aided by aqua divestiture proceeds and debt paydown.
- Pet health revenue $486M (-2% organic); Farm animal $530M (+3% organic); cattle up 6% on Experior and Rumensin.

## SEC filing metadata
- accession: 0001739104-24-000036
- form_type: 8-K
- ticker: ELAN
- cik: 0001739104
- company_name: Elanco Animal Health Inc
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739104/000173910424000036/0001739104-24-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739104/000173910424000036/elan-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001739104-24-000036
- JSON: https://secwatch.observer/filing/0001739104-24-000036.json
- Plain text: https://secwatch.observer/filing/0001739104-24-000036.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.